SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 30; pp. v908 - v910
Main Authors Nathan, P., Needham, A., Corrie, P.G., Danson, S., Evans, J., Ochsenreither, S., Kumar, S., Goodman, A., Larkin, J.M.G., Karydis, I., Steven, N.M., Lorigan, P., Plummer, R., Patel, P., Shaw, H.M., Leyvraz, S., Rawcliffe, C., Psarelli, E.E., Handley, L., Sacco, J.J.
Format Journal Article
LanguageEnglish
Published 01.10.2019
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
DOI:10.1093/annonc/mdz394.070